Arcturus Therapeutics' financial profile is defined by a high-intensity R&D burn rate consuming a finite cash reserve, with revenue exhibiting extreme lumpiness and lacking visibility. The company's liquidity buffer appears adequate on a headline basis with a ...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | -$0.84+15.7% vs -$1.00 | $3M-4.8% vs $3M |
Q2 2026 May 7, 2026 | -$0.95+7.4% vs -$1.03 | $2M-67.3% vs $6M |
Q2 2026 Mar 3, 2026 | -$1.03-12.0% vs -$0.92 | $7M-54.7% vs $16M |
Q4 2025 Nov 10, 2025 | -$0.49+38.7% vs -$0.80 | $17M+7.0% vs $16M |
Arcturus Therapeutics Holdings Inc. (the âCompanyâ, âArcturusâ, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that it will host a virtual presentation on Wednesday, September 23, 2026, at 4:30 p.m. ET. The presentation will provide an overview of the ARCT-810 Phase 2 clinical program for Ornithine transcarbamylase (OTC) deficiency and Arcturus' mRNA liver therapeutics pl.
Arcturus Therapeutics Holdings Inc. (ARCT) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Hsbc Holdings PLC acquired a new position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 56,895 shares of the biotechnology company's stock, valued at approximately $394,000. Hsbc Holdings PLC
Benchmark ARCT against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Arcturus Therapeutics Holdings Inc. (ARCT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $13.30 | $378.03M | -5.54 | -51.43% | -97.86% | -28.92% | — | |
| $182.11 | $72.26B | -25.08 | -39.23% | -141.43% | -39.2% | — | |
| $98.46 | $24.73B | -19.18 | 0.2% | -64.02% | -9.13% | — | |
| $12.33 | $1.38B | -3.24 | 16.92% | -672.16% | -57.79% | — | |
| $55.76 | $5.38B | -8.62 | -89.97% | -3368.72% | -24.39% | — | |
| $24.37 | $2.51B | -30.09 | 120.01% | -54.75% | -7.7% | — |
Arcturus Therapeutics Holdings Inc. (ARCT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Arcturus Therapeutics Holdings Inc. (ARCT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jul 2, 2026·SEC
Jun 5, 2026·SEC
Get notified when ARCT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Arcturus Therapeutics Holdings Inc. (ARCT) stock FAQ — growth, dividends, profitability & financials explained
Arcturus Therapeutics Holdings Inc. (ARCT) reported $23.8M in revenue for fiscal year 2025.
Arcturus Therapeutics Holdings Inc. (ARCT) saw revenue decline by 51.4% over the past year.
Arcturus Therapeutics Holdings Inc. (ARCT) reported a net loss of $93.3M for fiscal year 2025.
Arcturus Therapeutics Holdings Inc. (ARCT) has a return on equity (ROE) of -28.9%. Negative ROE indicates the company is unprofitable.
Arcturus Therapeutics Holdings Inc. (ARCT) had negative free cash flow of $92.5M in fiscal year 2025, likely due to heavy capital investments.
